MA50611A - Adaptateur d'écoulement destiné à un dispositif d'administration de médicament - Google Patents

Adaptateur d'écoulement destiné à un dispositif d'administration de médicament

Info

Publication number
MA50611A
MA50611A MA050611A MA50611A MA50611A MA 50611 A MA50611 A MA 50611A MA 050611 A MA050611 A MA 050611A MA 50611 A MA50611 A MA 50611A MA 50611 A MA50611 A MA 50611A
Authority
MA
Morocco
Prior art keywords
delivery device
drug delivery
flow adapter
adapter
flow
Prior art date
Application number
MA050611A
Other languages
English (en)
Inventor
Carl Conrath
Ali Nekouzadeh
Basel Hasan Taha
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA50611A publication Critical patent/MA50611A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
    • A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons pressurised by means of pistons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
    • A61M5/16804—Active flow controllers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
    • A61M5/16804—Active flow controllers
    • A61M5/16813—Active flow controllers by controlling the degree of opening of the flow line
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • A61M2005/14252—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type with needle insertion means

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MA050611A 2017-10-04 2018-09-26 Adaptateur d'écoulement destiné à un dispositif d'administration de médicament MA50611A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762567977P 2017-10-04 2017-10-04

Publications (1)

Publication Number Publication Date
MA50611A true MA50611A (fr) 2020-08-12

Family

ID=63858140

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050611A MA50611A (fr) 2017-10-04 2018-09-26 Adaptateur d'écoulement destiné à un dispositif d'administration de médicament

Country Status (5)

Country Link
US (1) US11759565B2 (fr)
EP (1) EP3691717B1 (fr)
ES (1) ES2939292T3 (fr)
MA (1) MA50611A (fr)
WO (1) WO2019070472A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005023458D1 (de) 2005-09-12 2010-10-21 Unomedical As Einfürungssystem für ein Infusionsset mit einem ersten und zweiten Federeinheit
US10194938B2 (en) 2011-03-14 2019-02-05 UnoMedical, AS Inserter system with transport protection
CN112545886A (zh) 2015-03-10 2021-03-26 里珍纳龙药品有限公司 无菌刺穿系统和方法
CA3055583A1 (fr) 2017-05-05 2018-11-08 Regeneron Pharmaceuticals, Inc. Auto-injecteur
EP3972672A4 (fr) 2019-05-20 2023-06-21 Unomedical A/S Dispositif de perfusion rotative et méthodes associées
US20220355033A1 (en) * 2019-06-21 2022-11-10 Preci Health Sa Medical injection system and method
US12594379B2 (en) 2019-09-12 2026-04-07 Amgen Inc. Backflow prevention mechanism for drug delivery device
EP4041341A1 (fr) * 2019-10-08 2022-08-17 Amgen Inc. Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
US11872369B1 (en) 2021-02-18 2024-01-16 Fresenius Kabi Deutschland Gmbh Wearable medicament delivery device with leakage and skin contact sensing and method of use thereof
US11311666B1 (en) 2021-02-18 2022-04-26 Fresenius Kabi Deutschland Gmbh Modular wearable medicament delivery device and method of use thereof
US11464902B1 (en) 2021-02-18 2022-10-11 Fresenius Kabi Deutschland Gmbh Wearable medicament delivery device with compressible reservoir and method of use thereof
US11607505B1 (en) 2021-02-19 2023-03-21 Fresenius Kabi Deutschland Gmbh Wearable injector with sterility sensors
US11497847B1 (en) 2021-02-19 2022-11-15 Fresenius Kabi Deutschland Gmbh Wearable injector with adhesive substrate
US11413394B1 (en) 2021-02-19 2022-08-16 Fresenius Kabi Deutschland Gmbh Display for wearable drug delivery device
US11406755B1 (en) 2021-02-19 2022-08-09 Fresenius Kabi Deutschland Gmbh Sensing fluid flow irregularities in an on-body injector
US11426523B1 (en) 2021-02-19 2022-08-30 Fresenius Kabi Deutschland Gmbh Drug delivery assembly including a removable cartridge
US11344682B1 (en) 2021-02-19 2022-05-31 Fresenius Kabi Deutschland Gmbh Drug supply cartridge with visual use indicator and delivery devices that use the same
US11633537B1 (en) 2021-02-19 2023-04-25 Fresenius Kabi Deutschland Gmbh Drug delivery assembly including a pre-filled cartridge
US11419976B1 (en) 2021-04-30 2022-08-23 Fresenius Kabi Deutschland Gmbh Wearable drug delivery device with pressurized fluid dispensing
US11529459B1 (en) 2021-04-30 2022-12-20 Fresenius Kabi Deutschland Gmbh Wearable injector with adhesive module
US11351300B1 (en) 2021-04-30 2022-06-07 Fresenius Kabl Deutschland GmbH Drug dispensing system with replaceable drug supply cartridges
US11504470B1 (en) 2021-04-30 2022-11-22 Fresenius Kabi Deutschland Gmbh Deformable drug reservoir for wearable drug delivery device
US11717608B1 (en) 2021-05-03 2023-08-08 Fresenius Kabi Deutschland Gmbh Drug delivery assembly including an adhesive pad
US11484646B1 (en) 2021-05-04 2022-11-01 Fresenius Kabi Deutschland Gmbh Sealing systems for a reservoir of an on-body injector
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
WO2024259313A1 (fr) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Emballage de dispositif médical et procédés associés

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1063008A (en) 1913-03-15 1913-05-27 William E Budd Vehicle-tire.
US4451255A (en) * 1982-05-20 1984-05-29 Abbott Laboratories Dual flow rate intravenous administration set with single pump chamber
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6186982B1 (en) 1998-05-05 2001-02-13 Elan Corporation, Plc Subcutaneous drug delivery device with improved filling system
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6391633B1 (en) 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US6030086A (en) 1998-03-02 2000-02-29 Becton, Dickinson And Company Flash tube reflector with arc guide
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
DK1088084T3 (da) 1998-06-15 2007-01-29 Gtc Biotherapeutics Inc Erythropoietin analog-humant serumalbumin fusionsprotein
DE69935345T3 (de) 1998-10-23 2018-03-01 Amgen Inc. Methoden und zusammensetzungen zur prävention und behandlung der anämie
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
EP1006184A1 (fr) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag Protéines interagissant avec le récepteur de IGF-1, gènes codant pour ces protéines et leurs utilisations
EP1169352A4 (fr) 1999-04-14 2005-05-04 Smithkline Beecham Corp Anticorps du recepteur d'erythropoietine
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6416293B1 (en) * 1999-07-20 2002-07-09 Deka Products Limited Partnership Pumping cartridge including a bypass valve and method for directing flow in a pumping cartridge
AU1099601A (en) 1999-10-22 2001-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (fr) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Formes d'erythropoietine dotees de proprietes ameliorees
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU5551601A (en) 2000-04-21 2001-11-07 Amgen Inc Methods and compositions for the prevention and treatment of anemia
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US20030191291A1 (en) 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
US7271689B1 (en) 2000-11-22 2007-09-18 Fonar Corporation Magnet structure
EP1345628B1 (fr) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugues d'erythropoietine (epo) avec polyethylene glycol (peg)
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
JP2005503127A (ja) 2001-04-04 2005-02-03 ジェンオディセ エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド
HU229910B1 (hu) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
US6582393B2 (en) * 2001-05-29 2003-06-24 Therafuse, Inc. Compensating drug delivery system
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
KR100911951B1 (ko) 2001-08-23 2009-08-13 젠맵 에이/에스 인터루킨 15 (ｉｌ-15)에 대하여 특이적인 인간 항체
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003055526A2 (fr) 2001-12-21 2003-07-10 Maxygen Aps Conjugues d'erythropoietine
ES2283759T3 (es) 2002-01-18 2007-11-01 Pierre Fabre Medicament Anticuerpos anti-igf-ir y sus aplicaciones.
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP1470232A1 (fr) 2002-01-31 2004-10-27 Oxford Biomedica (UK) Limited Vecteur d'expression de l'erythropoietine physiologiquement regule, destine au traitement de l'anemie
GB0202252D0 (en) 2002-01-31 2002-03-20 Oxford Biomedica Ltd Anemia
ATE363541T1 (de) 2002-03-26 2007-06-15 Lek Tovarna Farmacevtskih Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
WO2003084477A2 (fr) 2002-03-29 2003-10-16 Centocor, Inc. Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
KR100954975B1 (ko) 2002-03-29 2010-04-30 구미아이 가가쿠 고교 가부시키가이샤 아세토락테이트 합성효소를 암호화하는 유전자
US7350535B2 (en) * 2002-04-26 2008-04-01 Gl Tool And Manufacturing Co. Inc. Valve
WO2003094858A2 (fr) 2002-05-13 2003-11-20 Modigenetech Ltd. Érythropoïétine comportant une extension ctp
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
JP2005527755A (ja) 2002-05-24 2005-09-15 マイクロリス コーポレイション 質量流量メータのためのスロット付流量制限器
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7241733B2 (en) 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
WO2004002417A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
WO2004009627A1 (fr) 2002-07-19 2004-01-29 Cangene Corporation Composes erythropoietiques pegyles
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
WO2005025606A1 (fr) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene
MXPA05002594A (es) 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
TWI320716B (en) 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
WO2004034988A2 (fr) 2002-10-16 2004-04-29 Amgen Inc. Anticorps humains neutralisants anti-ifn-$g(g) utilises comme inhibiteurs selectifs des voies de ifn-$g(g)
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
AU2003301195B2 (en) 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
BRPI0408317A (pt) 2003-03-14 2006-03-07 Pharmacia Corp anticorpos do receptor de igf-i para o tratamento de cáncer
CA2519113C (fr) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EP2365001A3 (fr) 2003-05-01 2012-03-28 Imclone LLC Anticorps humains dirigés contre le récepteur de facteur 1 de croissance de type insuline humaine
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PL1625156T3 (pl) 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
KR101163683B1 (ko) 2003-05-12 2012-07-10 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 신규의 펩티드
JP2007530440A (ja) 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
WO2004108667A2 (fr) 2003-05-30 2004-12-16 Centocor, Inc. Formation de nouveaux conjugues d'erythropoietine au moyen d'une transglutaminase
WO2005001136A1 (fr) 2003-06-04 2005-01-06 Irm Llc Methodes et compositions pour la modulation de l'expression de l'erythropoietine
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
UA97086C2 (uk) 2003-07-15 2012-01-10 Емджен, Інк. Виділене людське антитіло, яке специфічно зв'язується з фактором росту нервової тканини (ngf)
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
JP2007512001A (ja) 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Ｅｐｏミメティックペプチドおよび融合タンパク質
US20060127404A1 (en) 2003-09-30 2006-06-15 Chichi Huang Hinge core mimetibodies, compositions, methods and uses
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
NZ547168A (en) 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
WO2005058967A2 (fr) 2003-12-16 2005-06-30 Pierre Fabre Medicament Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
EP1548031A1 (fr) 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Erythropoietin identique à la nature
EP1699920A4 (fr) 2003-12-31 2008-05-28 Centocor Inc Nouvelles proteines recombinees avec thiol libre n-terminal
EP1699821B1 (fr) 2003-12-31 2012-06-20 Merck Patent GmbH PROTEINE HYBRIDE Fc-ERYTHROPOIETINE A PHARMACOCINETIQUE AMELIOREE
US7423139B2 (en) 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
WO2005070451A1 (fr) 2004-01-22 2005-08-04 Zafena Aktiebolag Composition pharmaceutique comprenant une erythropoietine non glycosylee
WO2005084711A1 (fr) 2004-03-02 2005-09-15 Chengdu Institute Of Biological Products Erythropoietine recombinante pegylee a activite in vivo
TW200603818A (en) 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
CA2560889A1 (fr) 2004-03-23 2005-10-13 Sanjay D. Khare Anticorps monoclonaux
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
CA2563874A1 (fr) 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Variants d'erythropoietine
EP1781697B1 (fr) 2004-07-07 2009-04-22 H.Lundbeck A/S Nouvelle erythropoietine carbamylee et son procede de production
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US20060073563A1 (en) 2004-09-02 2006-04-06 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
AU2005303887A1 (en) 2004-11-10 2006-05-18 Aplagen Gmbh Molecules which promote hematopoiesis
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2006081171A1 (fr) 2005-01-24 2006-08-03 Amgen Inc. Anticorps anti-amyloide humanise
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CA2678008C (fr) 2005-06-17 2013-07-30 Imclone Systems Incorporated Antagonistes de recepteur pour le traitement de cancer osseux metastatique
WO2007000328A1 (fr) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
CN103255162A (zh) 2006-05-19 2013-08-21 格利科菲公司 促红细胞生成素组合物
US7736338B2 (en) * 2006-08-23 2010-06-15 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
CA2667894A1 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
CA2667869A1 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008133647A2 (fr) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonistes de pcsk9
WO2008057457A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
AR066042A1 (es) 2007-04-13 2009-07-22 Novartis Ag Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
US8016790B2 (en) 2007-04-20 2011-09-13 Carefusion 303, Inc. Infusion status indicator
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
US20130072665A1 (en) 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CN102232088A (zh) 2007-10-26 2011-11-02 先灵公司 用于治疗脂类和胆固醇疾病的抗pcsk9及方法
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
EP2296694B1 (fr) 2008-04-23 2015-08-05 Amgen Inc. Variants neutralisants de la proprotéine convertase subtilisine/kexine de type 9 (pcsk9) et ses applications
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
US20100137842A1 (en) * 2008-12-02 2010-06-03 Gibson Scott R Ambulatory Infusion Devices With Improved Delivery Accuracy
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
AU2010313324A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX213 and AX132 PCSK9 antagonists and variants
CA2777698A1 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afferentes
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
ES2545411T5 (es) * 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
WO2012054438A1 (fr) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
US8613308B2 (en) 2010-12-10 2013-12-24 Uop Llc Process for transferring heat or modifying a tube in a heat exchanger
CN103261230A (zh) 2010-12-22 2013-08-21 霍夫曼-拉罗奇有限公司 抗pcsk9抗体及使用方法
CA2825778A1 (fr) 2011-01-28 2012-08-02 Sanofi Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9
MX2013009258A (es) 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EP3907237A1 (fr) 2012-12-20 2021-11-10 Amgen Inc. Agonistes du récepteur apj et leurs utilisations
SG11201507524TA (en) 2013-03-14 2015-10-29 Amgen Inc Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
US20140274874A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
AU2014235430A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
WO2015027174A1 (fr) * 2013-08-23 2015-02-26 Unitract Syringe Pty Ltd Raccordement de voie de fluide à joint perforable intégré et récipients de médicament pour pompes d'administration de médicament
CN105848694B (zh) 2013-11-15 2020-01-24 艾韦尼克斯股份有限公司 流体控制系统和一次性组件
KR20240067287A (ko) 2017-04-27 2024-05-16 스냅 인코포레이티드 소셜 미디어 플랫폼들을 위한 친구 위치 공유 메커니즘

Also Published As

Publication number Publication date
ES2939292T3 (es) 2023-04-20
EP3691717B1 (fr) 2023-02-08
US11759565B2 (en) 2023-09-19
EP3691717A1 (fr) 2020-08-12
US20200297927A1 (en) 2020-09-24
WO2019070472A1 (fr) 2019-04-11

Similar Documents

Publication Publication Date Title
EP3793680C0 (fr) Dispositif d'administration de radio-embolisation
MA51900A (fr) Dispositif d'administration de médicament à élément détecté
MA49949A (fr) Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
MA50904A (fr) Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
EP3520843A4 (fr) Dispositif d'administration de médicament liquide
EP3826589A4 (fr) Dispositif ophtalmique pour l'administration de médicaments
MA53912A (fr) Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
MA51617A (fr) Mécanisme d'administration de médicament
MA50614A (fr) Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
EP3870263A4 (fr) Dispositif d'administration
MA47679A (fr) Détection de dose et identification de médicament pour dispositif d'administration de médicament
EP3534808A4 (fr) Dispositif d'administration d'ondes mécaniques à travers un cathéter à ballonnet
EP3437676A4 (fr) Dispositif d'administration de médicament liquide
EP3777932A4 (fr) Dispositif d'administration de médicament par microjet électrohydraulique
MA51131A (fr) Dispositif d'administration de médicament doté d'un système de détection de seringue
MA53818A (fr) Dispositif d'administration de médicament ayant un indicateur de dose
EP3664867A4 (fr) Accessoire de communication pour un dispositif d'administration de médicament
EP3354302A4 (fr) Dispositif d'administration de médicament liquide
MA53227A (fr) Mécanisme d'activation pour dispositif d'administration de médicament
EP3881883A4 (fr) Dispositif d'administration de solution medicamenteuse
FR3016125B1 (fr) Dispositif d'administration de fluides ou de substances a visee orl
SG11202005291WA (en) Priming system for drug delivery device
EP3886774A4 (fr) Système amélioré d'administration de fluide
ZA202104682B (en) Nasal drug delivery device
EP3691641A4 (fr) Dispositif d'administration transdermique de dextrométhorphane